Also listed on Genoa Corporation, an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Jan 31, 2032 · High confidence
20-year base term ends Jan 31, 2032
Held by Avalyn Pharma Inc.
Filed Oct 3, 2018 as application 16/151,141 · Granted Jan 18, 2022
Base term, 20 years from filing
Today
2012
2032
Clock starts
Jan 31, 2012
Jan 31, 2012
Term ends
Jan 31, 2032
Jan 31, 2032
Granted
Jan 18, 2022
Jan 18, 2022
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 10,092,552, to Jan 31, 2032. The term already ends on or before that date, so the cap shortened nothing.
1 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
9
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 2 maintenance fees is paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jan 31, 2012, when application 13/363,311, the earliest non-provisional in its chain, was filed (this one was filed Oct 3, 2018) | Jan 31, 2032 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,092,552) | resolves to Jan 31, 2032, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jan 31, 2032 | High confidence |
This family
| US 10,092,552 | In force Apr 2032 | Apr 2032 |
| US 10,105,356 | In force Apr 2032 | Apr 2032 |
| US 11,224,592 | this patent Jan 2032 | Jan 2032 |
| Application 16/167,337 | Abandoned not computed | not computed |
| US 11,452,718 | In force Jan 2032 | Jan 2032 |
| US 11,559,520 | In force Jan 2032 | Jan 2032 |
| Application 17/576,830 | Pending not computed | not computed |
| US 12,226,407 | In force Jan 2032 | Jan 2032 |
8 of 9 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Mar 19, 2019 Reel 48641, frame 556 | Surber, Mark William | Genoa Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Mar 19, 2019 Reel 48642, frame 670 | Genoa Pharmaceuticals, Inc. | Avalyn Pharma Inc. | Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Jan 2032
Term ends Jan 31, 2032. Maintenance fees still fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 10,092,552, ends no earlier than this term, so it caps nothing.
Citations
14
later US patents cite this one
That is top 10% of utility patents granted in 2022 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.